Adamis Pharmaceuticals

Its specialty pharmaceutical division currently has four products in its pipeline including the Epinephrine Injection Pre-filled Syringe (PFS) for use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000 (Dry Powder Inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (COPD), and APC-3000, a hydrofluoroalkane (HFA) inhaled nasal steroid product for the treatment of allergic rhinitis. This division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. Adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. Within its biotechnology division, the Company has four products under development include TeloB-VAX, a novel cell-based therapeutic cancer vaccine for prostate cancer and three drugs, APC-100, APC-200, and APC-300, for the treatment of prostate cancer.
San Diego, US
15 (est)+16%

Key People at Adamis Pharmaceuticals

Robert O. Hopkins

Robert O. Hopkins

Dennis J. Carlo

Dennis J. Carlo


Adamis Pharmaceuticals Locations

San Diego, US

Adamis Pharmaceuticals Metrics

Adamis Pharmaceuticals Summary

Founding Date


Market capitalization

$58.5 M

Closing share price


Adamis Pharmaceuticals Market Value History

Adamis Pharmaceuticals News

Adamis Pharmaceuticals Company Life